Clinical and Pathologic Risk Factors of Tumor Recurrence in Patients With Node-Negative Early Breast Cancer After Mastectomy

被引:14
作者
Lin, Po-Han [1 ,2 ,3 ,4 ]
Yeh, Ming-Hsin [5 ]
Liu, Liang-Chih [5 ]
Chen, Chih-Jung [5 ]
Tsui, Yu-Chu [5 ]
Su, Chen-Hsien [5 ]
Wang, Hwei-Chung [5 ]
Liang, Ji-An [6 ]
Chang, Hui-Wen [7 ]
Wu, Hsiao-Su [5 ]
Yeh, Su-Peng [3 ,8 ]
Li, Long-Yuan [9 ,10 ]
Chiu, Chang-Fang [3 ,8 ]
机构
[1] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan
[2] China Med Univ Hosp, Dept Med Genet, Taichung 40447, Taiwan
[3] China Med Univ Hosp, Dept Internal Med, Div Hematol & Oncol, Taichung 40447, Taiwan
[4] Natl Taiwan Univ Hosp, Dept Med Genet, Taipei, Taiwan
[5] China Med Univ Hosp, Dept Surg, Taichung 40447, Taiwan
[6] China Med Univ Hosp, Dept Radiat Oncol, Taichung 40447, Taiwan
[7] China Med Univ Hosp, Dept Pathol, Taichung 40447, Taiwan
[8] China Med Univ, Coll Med, Taichung, Taiwan
[9] China Med Univ, Ctr Mol Med, Taichung, Taiwan
[10] China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan
关键词
node-negative; breast cancer; lymphovascular invasion; grade; radiotherapy; PERITUMORAL VASCULAR INVASION; PROGNOSTIC VALUE; POSTMASTECTOMY RADIOTHERAPY; LOCOREGIONAL RECURRENCE; ADJUVANT THERAPY; ST-GALLEN; FOLLOW-UP; EXPRESSION; GRADE; CYCLOPHOSPHAMIDE;
D O I
10.1002/jso.23403
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and ObjectivesPatients with node-negative breast cancer (NNBC) usually have a good prognosis, but tumor recurrence still compromises survival. In this study, we sought to identify clinical and pathologic factors that predict recurrence. MethodsA total of 716 patients who were proved with pT1-2N0M0 breast cancer between 2005 and 2009 were enrolled in this study. ResultsForty-seven of the 716 patients developed tumor recurrence during the 47.0 months of median follow-up. The significant risk factors of recurrence were lymphovascular invasion (LVI) (hazard ratio [HR]=4.60, 95% CI. 2.32-9.10) and Nottingham grade 3 (HR=4.99, 95% CI. 1.06-23.48); adjuvant radiotherapy (HR=0.35, 95% CI. 0.14-0.92) prevented tumor recurrence. Furthermore, we investigate the therapeutic impact of adjuvant chemotherapy and radiotherapy on patients with LVI and Nottingham grade 3. The adverse effect of LVI and grade 3 can be abrogated by adjuvant radiotherapy in recurrence-free survival (RFS) (LVI((+))radiotherapy((+)), no recurrence; grade 3((+))radiotherapy((+)), HR=0.82, 95% CI. 0.18-3.70). However, adjuvant chemotherapy did not. ConclusionsLVI and Nottingham grade 3 were the independent risk factors predicting tumor recurrence for patients with NNBC. Adjuvant radiotherapy might be considered in NNBC patients with these unfavorable factors to improve the RFS. J. Surg. Oncol. 2013; 108:352-357. (c) 2013 Wiley Periodicals, Inc.
引用
收藏
页码:352 / 357
页数:6
相关论文
共 24 条
[1]   Increased Risk of Locoregional Recurrence for Women With T1-2N0 Triple-Negative Breast Cancer Treated With Modified Radical Mastectomy Without Adjuvant Radiation Therapy Compared With Breast-Conserving Therapy [J].
Abdulkarim, Bassam S. ;
Cuartero, Julie ;
Hanson, John ;
Deschenes, Jean ;
Lesniak, David ;
Sabri, Siham .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (21) :2852-2858
[2]  
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[3]   Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Aebi, S. ;
Davidson, T. ;
Gruber, G. ;
Cardoso, F. .
ANNALS OF ONCOLOGY, 2011, 22 :vi12-vi24
[4]   Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer [J].
Colleoni, M. ;
Rotmensz, N. ;
Maisonneuve, P. ;
Sonzogni, A. ;
Pruneri, G. ;
Casadio, C. ;
Luini, A. ;
Veronesi, P. ;
Intra, M. ;
Galimberti, V. ;
Torrisi, R. ;
Andrighetto, S. ;
Ghisini, R. ;
Goldhirsch, A. . ;
Viale, G. .
ANNALS OF ONCOLOGY, 2007, 18 (10) :1632-1640
[5]   Survival Benefit of Post-mastectomy Radiotherapy in Breast Carcinoma Patients with T1-2 Tumor and 13 Axillary Lymph Node(s) Metastasis [J].
Duraker, Nuvit ;
Demir, Davut ;
Bati, Bakir ;
Yilmaz, Binnur Donmez ;
Bati, Yasemin ;
Caynak, Zeynep Civelek ;
Sobutay, Erman .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (07) :601-608
[6]   Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 [J].
Ferlay, Jacques ;
Shin, Hai-Rim ;
Bray, Freddie ;
Forman, David ;
Mathers, Colin ;
Parkin, Donald Maxwell .
INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (12) :2893-2917
[7]   Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis [J].
Gamucci, T. ;
Vaccaro, A. ;
Ciancola, F. ;
Pizzuti, L. ;
Sperduti, I. ;
Moscetti, L. ;
Longo, F. ;
Fabbri, M. A. ;
Giampaolo, M. A. ;
Mentuccia, L. ;
Di Lauro, L. ;
Vici, P. .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (05) :853-860
[8]   Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [J].
Goldhirsch, A. ;
Wood, W. C. ;
Coates, A. S. ;
Gelber, R. D. ;
Thuerlimann, B. ;
Senn, H. -J. .
ANNALS OF ONCOLOGY, 2011, 22 (08) :1736-1747
[9]   Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 [J].
Jänicke, F ;
Prechtl, A ;
Thomssen, C ;
Harbeck, N ;
Meisner, C ;
Untch, M ;
Sweep, CGJF ;
Selbmann, HK ;
Graeff, H ;
Schmitt, M .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (12) :913-920
[10]  
Joensuu H, 1999, CANCER-AM CANCER SOC, V85, P2183, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2183::AID-CNCR12>3.0.CO